GlycoMimetics, Inc. (GLYC) reported topline results from Phase 3 global pivotal study of uproleselan in 388 patients with Relapsed/Refractory Acute Myeloid Leukemia. The company said, in the study, uproleselan combined with chemotherapy did not achieve a statistically significant improvement in overall survival in the intent to treat population versus chemotherapy alone.
The company also disclosed preliminary financial results for the first quarter of 2024. Research and development expenses increased to $6.0 million for the quarter as compared to $5.4 million for the same period in 2023. As of March 31, 2024, GlycoMimetics had cash and cash equivalents of $31.3 million.
Shares of GlycoMimetics are down 51% in pre-market trade on Monday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.